CSF complement 3 and factor H are staging biomarkers in Alzheimer’s disease-Reference-Cited by-同舟云学术

CSF complement 3 and factor H are staging biomarkers in Alzheimer’s disease

Published:2016-02-17 Issue:1 Volume:4 Page:
ISSN:2051-5960
Container-title:Acta Neuropathologica Communications
language:en
Short-container-title:acta neuropathol commun

Author:

Hu William T., ,Watts Kelly D.,Tailor Prashant,Nguyen Trung P.,Howell Jennifer C.,Lee Raven C.,Seyfried Nicholas T.,Gearing Marla,Hales Chadwick M.,Levey Allan I.,Lah James J.,Lee Eva K.

Funder

National Institute on Aging

American Federation for Aging Research

Publisher

Springer Science and Business Media LLC

Subject

Cellular and Molecular Neuroscience,Neurology (clinical),Pathology and Forensic Medicine

Link

http://link.springer.com/content/pdf/10.1186/s40478-016-0277-8.pdf

Reference40 articles.

1. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):270–9.

2. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009;65(4):403–13.

3. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):280–92.

4. Buchhave P, Blennow K, Zetterberg H, Stomrud E, Londos E, Andreasen N, et al. Longitudinal study of CSF biomarkers in patients with Alzheimer's disease. PLoS One. 2009;4(7), e6294.

5. Zetterberg H, Pedersen M, Lind K, Svensson M, Rolstad S, Eckerstrom C, et al. Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years. J Alzheimers Dis. 2007;12(3):255–60.

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of Preanalytical Procedures on Complement Biomarkers in Cerebrospinal Fluid and Plasma from Controls and Alzheimer’s Disease Patients;Journal of Alzheimer's Disease;2024-09-10

2. The complement system in neurodegenerative diseases;Clinical Science;2024-03

3. Subsequent correlated changes in complement component 3 and amyloid beta oligomers in the blood of patients with Alzheimer's disease;Alzheimer's & Dementia;2024-02-27

4. Validating blood tests as a possible routine diagnostic assay of Alzheimer’s disease;Expert Review of Molecular Diagnostics;2023-12

5. Systematic review: fluid biomarkers and machine learning methods to improve the diagnosis from mild cognitive impairment to Alzheimer’s disease;Alzheimer's Research & Therapy;2023-10-14